Showing 4431-4440 of 7767 results for "".
- LEO Pharma Data: Tralokinumab Benefits Adult ADhttps://practicaldermatology.com/news/leo-pharma/2460662/Results from a post-hoc subanalysis of the Phase 3 ECZTRA 3 trial demonstrate the potential for LEO Pharma’s tralokinumab as a treatment for adults with moderate-to-severe atopic dermatitis. Investigational tralokinumab has not y
- RealSelf Acquires Tajmeeli.com to Serve Arabic-Speaking Medical Aesthetics Markethttps://practicaldermatology.com/news/realself-acquires-tajmeelicom-to-aerve-arabic-speaking-medical-aesthetics-market/2460660/RealSelf now owns Tajmeeli, the leading cosmetic procedure resource for Arabic speaking consumers. The acquisition adds one million Arabic-speaking monthly active users. "We're excited this acquisition will enable us to expand our reach and resources to over 100 countries
- Cyspera Demonstrates Efficacy, Safety in Three Published Studieshttps://practicaldermatology.com/news/cyspera-demonstrates-efficacy-safety-in-three-published-studies/2460657/Several studies recently published in peer reviewed journals demonstrate the safety and efficacy of stabilized-cysteamine 5% cream (Cyspera), the novel, non-hydroquinone, topical pigment regulator from Scientis In a randomized, double-blinded study of 50 melasma patients assigned to eit
- Novartis: Ligelizumab Receives Breakthrough Therapy Designation in CSUhttps://practicaldermatology.com/news/novartis-ligelizumab-receives-breakthrough-therapy-designation-in-csu/2460656/Ligelizumab from Novartis now has Breakthrough Therapy designation from FDA for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. Ligelizumab
- Arcutis Starts Phase 3 Trials of Topical Roflumilast Cream for ADhttps://practicaldermatology.com/news/arcutis-starts-phase-3-trials-of-topical-roflumilast-cream-for-ad/2460654/Arcutis Biotherapeutics, Inc. is starting their pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- Fitness Level Tied to Psoriasis Riskhttps://practicaldermatology.com/news/fitness-level-tied-to-psoriasis-risk/2460653/Low fitness levels may increase risk for psoriasis, according to a register-based study of military recruits. Specifically, male recruits to compulsory military training who were rated as the least fit had a 35 percent higher risk for psoriasis when compared to the f
- Cerave Poll: Healthier Skin Tops New Year’s Resolutionshttps://practicaldermatology.com/news/cerave-poll-healthier-skin-tops-new-years-resolution-lists/2460652/The COVID-19 pandemic has taken its toll on every aspect of life including skin, according to a new survey from CeraVe. Fully 62 percent of Americans agree that they have experienced more skin troubles during the pandemic than ever before, with top concerns being dryness (51
- DermBiont Releases Positive Phase 2 Data for DBI-001 in Tinea pedis, Atopic dermatitishttps://practicaldermatology.com/news/dermbiont-releases-positive-phase-2-data-for-dbi-001-in-tinea-pedis-atopic-dermatitis/2460649/Data from two, separate phase 2 clinical trials of investigational DBI-001 for the treatment of tinea pedis and atopic dermatitis show benefit, according to drug developer DermBiont. In the phase 2b clinical study of DBI-001 in tinea p
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.